» Authors » Kevin Petrie

Kevin Petrie

Explore the profile of Kevin Petrie including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 1757
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Sbirkov Y, Vergov B, Dzharov V, Schenk T, Petrie K, Sarafian V
Int J Mol Sci . 2023 Feb; 24(4). PMID: 36834787
The prognosis for patients with relapsed childhood acute lymphoblastic leukaemia (cALL) remains poor. The main reason for treatment failure is drug resistance, most commonly to glucocorticoids (GCs). The molecular differences...
2.
Urban-Wojciuk Z, Graham A, Barker K, Kwok C, Sbirkov Y, Howell L, et al.
Cancer Gene Ther . 2021 Sep; 29(7):940-950. PMID: 34522028
Deregulated polyamine biosynthesis is emerging as a common feature of neuroblastoma and drugs targeting this metabolic pathway such as DFMO are in clinical and preclinical development. The polyamine analog verlindamycin...
3.
Brown G, Petrie K
Int J Mol Sci . 2021 Apr; 22(7). PMID: 33807298
Cancer "stem cells" (CSCs) sustain the hierarchies of dividing cells that characterize cancer. The main causes of cancer-related mortality are metastatic disease and relapse, both of which originate primarily from...
4.
Sbirkov Y, Ivanova T, Burnusuzov H, Gercheva K, Petrie K, Schenk T, et al.
Front Oncol . 2021 Apr; 11:632181. PMID: 33791218
Childhood acute lymphoblastic leukaemia (cALL) accounts for about one third of all paediatric malignancies making it the most common cancer in children. Alterations in tumour cell metabolism were first described...
5.
Petrie K, Urban-Wojciuk Z, Sbirkov Y, Graham A, Hamann A, Brown G
Cancer Rep (Hoboken) . 2020 Sep; 3(6):e1284. PMID: 32881426
Background: Prostate cancer (PC) tissue contains all-trans retinoic acid (ATRA) at a very low level (10 M), at least an order of magnitude lower than in adjacent normal healthy prostate...
6.
Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, et al.
Leukemia . 2020 Jan; 34(7):1972. PMID: 31949266
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, et al.
Leukemia . 2019 Oct; 33(11):2628-2639. PMID: 31576004
To date, only one subtype of acute myeloid leukemia (AML), acute promyelocytic leukemia (APL) can be effectively treated by differentiation therapy utilizing all-trans retinoic acid (ATRA). Non-APL AMLs are resistant...
8.
Watts J, Perez A, Pereira L, Fan Y, Brown G, Vega F, et al.
Int J Mol Sci . 2017 Jul; 18(7). PMID: 28696354
Here we report the case of a 30-year-old woman with relapsed acute myeloid leukemia (AML) who was treated with all- retinoic acid (ATRA) as part of investigational therapy (NCT02273102). The...
9.
Sbirkov Y, Kwok C, Bhamra A, Thompson A, Gil V, Zelent A, et al.
Int J Mol Sci . 2017 Jul; 18(7). PMID: 28678185
Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function and loss-of-function, have been linked to a variety of haematological malignancies and solid tumours, suggesting a complex, context-dependent...
10.
Gil V, Bhagat G, Howell L, Zhang J, Kim C, Stengel S, et al.
Dis Model Mech . 2016 Nov; 9(12):1483-1495. PMID: 27799148
Histone deacetylase 9 (HDAC9) is expressed in B cells, and its overexpression has been observed in B-lymphoproliferative disorders, including B-cell non-Hodgkin lymphoma (B-NHL). We examined HDAC9 protein expression and copy...